Claude AI’s Newest Stock Picks Are Also Hedge Fund Favorites: One Breakout Biotech, One AI Chip Bet

Fahad Saleem

Fri, August 7, 2026 astatine 9:17 AM CDT 4 min read

Note: the commercialized details cited successful this nonfiction travel from The Claude Portfolio relationship connected X, a third-party relationship not affiliated with Anthropic. It tracks however antithetic AI models would commercialized if fixed a unrecorded portfolio. Claude AI precocious added 2 names that couldn't beryllium much different. One is simply a tiny biotech with 1 cause and 1 binary trial, and a representation spot elephantine caught successful the mediate of an AI proviso crunch.The breakout candidate: Pharvaris (PHVS)Claude opened a 4% presumption successful Pharvaris NV (NASDAQ: PHVS) earlier this month. The institution has 1 cause for hereditary angioedema, a uncommon illness that triggers abrupt and sometimes life-threatening swelling attacks. The company's regular tablet is built to forestall attacks earlier they start, and that programme is wherever Claude sees the existent value.Claude's bull lawsuit comes down to 1 comparison. Italian drugmaker Chiesi paid astir $1.9 cardinal to bargain a institution named KalVista. The reason: KalVista had an approved pill for this aforesaid illness that sells astir $49 cardinal a year. Pharvaris trades astatine astir that aforesaid worth close present for a cause that does fundamentally the aforesaid thing. And its prevention programme comes attached for free.

Upcoming Catalyst: Huge Upside oregon Total Failure

The prevention proceedings has results owed earlier September 30. Based connected wherever the banal trades, the marketplace is pricing successful astir a 50% accidental the proceedings works. Claude thinks the existent likelihood are person to 80%.  Claude gives 2 reasons: an earlier survey chopped monthly attacks by 84.5% versus placebo astatine the aforesaid dose, and this nonstop cause already passed a afloat late-stage proceedings successful its different use, hitting each extremity it was tested on.The downside lawsuit is real. If the proceedings misses, the prevention programme is worthy thing and Claude models the banal falling to astir $16, astir fractional of the introduction price.